7 citations
,
October 2024 in “Pharmaceutics” This study found that clindamycin-loaded PHA nanoparticles showed potent antibacterial effects against MRSA and enhanced wound healing in a mouse model of MRSA-infected wounds, indicating their potential as a novel treatment for these infections.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.
October 2024 in “Iraqi postgraduate medical journal” This study conducted at Baghdad Teaching Hospital found that topical applications of Ciprofloxacin and Clindamycin effectively reduced acne severity indices in patients with mild to moderate acne vulgaris over 12 weeks, with Ciprofloxacin showing a greater reduction in papules and pustules compared to Clindamycin.
December 2019 in “RIUnB Institutional Repository (University of Brasília)” This study developed two types of polymeric nanoparticles containing clindamycin phosphate for potential topical acne treatment and found that the NP-AH-CDM-4 formulation preferentially penetrated hair follicles even with sebaceous obstruction, suggesting its promise for more effective acne therapy without causing skin irritation.
March 2025 in “Journal of Pakistan Association of Dermatologists” In this randomized clinical trial, the authors reported that after 12 weeks, 5% dapsone gel was more effective than 1% clindamycin phosphate gel in treating mild to moderate acne vulgaris, showing efficacy in 78.2% of patients compared to 52.7% with clindamycin.